SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-092275
Filing Date
2024-08-07
Accepted
2024-08-07 07:15:24
Documents
68
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q kymr-20240630.htm   iXBRL 10-Q 2560761
2 EX-31.1 kymr-ex31_1.htm EX-31.1 16334
3 EX-31.2 kymr-ex31_2.htm EX-31.2 16224
4 EX-32.1 kymr-ex32_1.htm EX-32.1 8991
5 EX-32.2 kymr-ex32_2.htm EX-32.2 8884
  Complete submission text file 0000950170-24-092275.txt   9600476

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kymr-20240630.xsd EX-101.SCH 1361955
71 EXTRACTED XBRL INSTANCE DOCUMENT kymr-20240630_htm.xml XML 1677494
Mailing Address 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472
Business Address 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472 857-285-5314
Kymera Therapeutics, Inc. (Filer) CIK: 0001815442 (see all company filings)

IRS No.: 812992166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39460 | Film No.: 241181419
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)